Table 2.

eGFR slope during the acute “dip” period (per week) and the readjustment period (per year), by baseline kidney status

Time PeriodeGFR G1
(eGFR≥90 ml/min per 1.73 m2)
eGFR G2
(eGFR≥60 and <90 ml/min per 1.73 m2)
eGFR G3
(eGFR<60 ml/min per 1.73 m2)
PlaceboErtugliflozinDifferenceaPlaceboErtugliflozinDifferenceaPlaceboErtugliflozinDifferencea
Weeks 0–6b−0.61−1.13−0.52−0.01−0.42−0.410.38−0.18−0.57
(−0.86 to −0.36)(−1.30 to −0.96)(−0.82 to −0.22)(−0.10 to 0.08)(−0.48 to −0.35)(−0.52 to −0.30)(0.26 to 0.50)(−0.27 to −0.10)(−0.72 to −0.42)
Weeks 6–52c−0.141.972.11−0.271.491.760.251.491.25
(−1.58 to 1.31)(0.95 to 3.00)(0.33 to 3.89)(−1.00 to 0.47)(0.98 to 2.00)(0.87 to 2.66)(−0.77 to 1.26)(0.76 to 2.22)(−0.01 to 2.50)
NormoalbuminuriaMicroalbuminuriaMacroalbuminuria
Weeks 0–6b−0.09−0.51−0.42−0.03−0.55−0.52−0.05−0.68−0.63
(−0.22 to 0.04)(−0.60 to −0.41)(−0.58 to −0.26)(−0.20 to 0.13)(−0.67 to −0.43)(−0.72 to −0.32)(−0.3 to 0.21)(−0.85 to −0.50)(−0.94 to −0.32)
Weeks 6–52c0.032.182.16−0.051.131.18−1.53−0.361.16
(−0.71 to 0.77)(1.66 to 2.71)(1.25 to 3.06)(−1.13 to 1.04)(0.36 to 1.90)(−0.15 to 2.51)(−3.59 to 0.54)(−1.78 to 1.05)(−1.34 to 3.66)
KDIGO CKD Low RiskKDIGO CKD Moderate RiskKDIGO CKD High/Very High Risk
Weeks 0–6b−0.23−0.60−0.37−0.00−0.51−0.510.22−0.42−0.64
(−0.37 to −0.08)(−0.70 to −0.50)(−0.55 to −0.19)(−0.18 to 0.17)(−0.63 to −0.39)(−0.72 to −0.30)(0.03 to 0.41)(−0.56 to −0.29)(−0.88 to −0.41)
Weeks 6–52c−0.082.122.20−0.081.531.62−0.350.380.73
(−0.92 to 0.76)(1.53 to 2.71)(1.17 to 3.23)(−1.16 to 0.99)(0.78 to 2.29)(0.30 to 2.93)(−1.59 to 0.89)(−0.49 to 1.25)(−0.78 to 2.25)
  • Analysis was performed on the full analysis set population. KDIGO CKD, Kidney Disease Improving Global Outcomes in Chronic Kidney Disease.

  • a Difference versus placebo (least squares mean [95% confidence interval]).

  • b eGFR slope (least squares mean), ml/min per 1.73 m2 per week (95% confidence interval).

  • c eGFR slope (least squares mean), ml/min per 1.73 m2 per year (95% confidence interval).